I’m a doctor — female nonsmokers get lung cancer more than men, look out for these troubling signs
November is Lung Cancer Awareness Month — an estimated 235,000 new cases of lung cancer and 125,000 deaths are expected to ...
MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or Metastatic NSCLC
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
News Medical on MSN6h
New algorithm identifies tumor cells driving aggressive cancer growth
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by Cancer Research UK-funded scientists from UCL and The Francis Crick ...
Cure Today1d
Tiragolumab Plus Tecentriq Misses Survival Endpoint for Lung Cancer Subset
The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...
BioPharma Dive7d
Roche’s TIGIT-targeting drug for cancer fails its biggest test
Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...
Community Impact Newspaper21h
2 UT Health SA scientists awarded grants for innovative cancer research
In recognition of their innovative cancer research, two scientists at the University of Texas Health Science Center at San ...
Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment
Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...